NASDAQ$CRVO
Diffusion Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
CervoMed reported first quarter 2024 financial results and provided corporate updates.
CervoMed reported its Q1 2024 financial results, highlighting the progress of the RewinD-LB Phase 2b clinical trial for neflamapimod in DLB patients, expected to complete enrollment in Q2 2024 with topline data anticipated in Q4 2024. The company completed a private placement of up to $149.4 million in early Q2 2024.
- On track to complete enrollment in RewinD-LB Phase 2b clinical trial in Q2 2024, with topline data expected in Q4 2024.
- Completed up to $149.4 million private placement with leading healthcare investors in early Q2 2024.
- Published integrated summary of results from AscenD-LB Phase 2a clinical trial in Neurology®.
- Cash and cash equivalents, along with NIA grant funds, are expected to provide runway through the end of 2025.
Headline financials
Revenue & EPS history
CervoMed · Revenue · Quarterly
$2.35M
Forward guidance
CervoMed anticipates completing enrollment in the RewinD-LB trial during the second quarter of 2024 and expects topline efficacy results in the fourth quarter of 2024. The company also plans to explore opportunities to expand the therapeutic applications of neflamapimod.
Tailwinds
- Completing enrollment in RewinD-LB trial in Q2 2024
- Topline efficacy results expected in Q4 2024
- Exploring expanded therapeutic applications of neflamapimod
- Cash runway through the end of 2025
- Phase 2b study funded by a $21.0 million grant
Headwinds
- Risks related to clinical trial outcomes
- Dependence on regulatory approval of neflamapimod
- Potential for delays in clinical and development milestones
- Risks related to available cash resources
- General economic and market conditions
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
+0.4%
Avg return
Earnings day
+177.7%
Avg return
5 days after
-10.0%
Avg return
30 days after
31%
20 / 65 earnings
Positive
+39.3%
Q1 2020
Best reaction
-27.6%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.5% | — | — | |
| Q4 2025 | +5.1% | -6.7% | -7.4% | |
| Q3 2025 | -0.3% | +11.0% | +25.3% | |
| Q2 2025 | +5.5% | +3.2% | +12.5% | |
| Q1 2025 | +0.0% | -4.1% | -17.3% | |
| Q4 2024 | +3.2% | +57.9% | +8.3% | |
| Q3 2024 | -7.6% | -11.3% | -84.1% | |
| Q2 2024 | +33.0% | +61.9% | +39.3% | |
| Q1 2024 | -1.4% | -20.1% | -23.0% | |
| Q4 2023 | -4.9% | -12.0% | +3.7% | |
| Q3 2023 | -2.6% | +0.2% | -10.6% | |
| Q2 2023 | -1.1% | +9.5% | +10.4% | |
| Q1 2023 | -5.4% | -1.7% | -11.3% | |
| Q4 2022 | -8.7% | -12.7% | -27.1% | |
| Q3 2022 | +21.4% | +22.0% | +28.6% | |
| Q2 2022 | -2.0% | -1.4% | -7.1% | |
| Q1 2022 | +18.6% | +25.5% | +25.5% | |
| Q4 2021 | -3.7% | +0.0% | -43.0% | |
| Q3 2021 | -6.7% | -4.4% | -15.6% | |
| Q2 2021 | -7.0% | -14.0% | -3.5% | |
| Q1 2021 | +0.0% | +6832.2% | +13.2% | |
| Q4 2020 | +4.9% | +4.9% | -99.1% | |
| Q3 2020 | -10.1% | -20.3% | -6.3% | |
| Q2 2020 | -0.9% | -1.8% | -22.7% | |
| Q1 2020 | +39.3% | +121.3% | +77.0% | |
| Q4 2019 | -8.8% | -17.6% | +17.6% | |
| Q3 2019 | -27.6% | -69.7% | -25.0% | |
| Q2 2019 | -0.9% | -3.7% | -10.6% | |
| Q1 2019 | -4.9% | -3.8% | -29.6% | |
| Q4 2018 | +3.8% | -4.3% | -33.6% | |
| Q3 2018 | +0.0% | -12.1% | -41.8% | |
| Q2 2018 | +2.8% | +13.9% | +11.1% | |
| Q4 2017 | -3.6% | -11.3% | -1.9% | |
| Q1 2018 | -3.6% | +1.8% | +1.8% | |
| Q3 2017 | -3.6% | -1.5% | +3.6% | |
| Q2 2017 | -7.7% | +0.0% | +12.5% | |
| Q4 2016 | -0.6% | +3.1% | -15.8% | |
| Q1 2017 | -0.6% | +3.1% | -15.8% | |
| Q3 2016 | -3.8% | -4.8% | -40.0% | |
| Q2 2016 | +0.0% | +0.0% | -90.0% | |
| Q1 2016 | +11.1% | — | — | |
| Q4 2015 | -6.4% | — | — | |
| Q3 2015 | -9.1% | — | — | |
| Q2 2015 | +1.2% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | -7.1% | — | — | |
| Q3 2014 | -1.1% | — | — | |
| Q2 2014 | +4.5% | — | — | |
| Q1 2014 | -3.2% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | +18.8% | — | — | |
| Q3 2012 | +4.8% | — | — | |
| Q2 2012 | -2.6% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +8.0% | — | — | |
| Q3 2011 | -11.5% | — | — | |
| Q2 2011 | +7.1% | — | — | |
| Q1 2011 | +5.5% | — | — | |
| Q4 2010 | +1.6% | — | — | |
| Q3 2010 | +19.0% | — | — | |
| Q2 2010 | -12.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro